All Resources

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more|View

Access to Medicine • June 28, 2022

pCPA overview of the Negotiation Process

Learn more about the negotiation process from the pCPA….

Learn more|View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more|View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more|View

Access to Medicine • December 01, 2021

Canadian public insurance plans and delays in patient access to innovative medicines

Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to…

Learn more|View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • August 31, 2021

PMPRB Notice and Comment Response

Learn more|View

Access to Medicine • August 06, 2021

2022 Federal Pre-Budget Consultation

Learn more|View

Private Drug Coverage • August 01, 2021

Cost Drivers: Analysis of Private Drug Plans in Canada 2021

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • June 21, 2021

Proposed Guidelines Monitoring and Evaluation Plan

Learn more|View

Economic Impact • May 30, 2021

The Canadian Research and Development Pharmaceutical Sector

Learn more|View

Vaccine Equity • April 30, 2021

Standing Committee on International Trade (CIIT) study of Canada’s International Trade and Investment Policy

Learn more|View